NOV-205 is in Phase 1b development for chronic hepatitis
Asian Americans account for more than half the chronic hepatitis
B cases, many of which can result in serious liver damage.
In the Mediterranean countries and Eastern Europe the HBeAg-negative form of chronic hepatitis
B, which is more difficult-to-treat and associated with a poorer prognosis, is particularly prevalent.
While liver tests (alanine aminotransferase, ALT) and other markers (hepatitis B e-antigen) have traditionally been used for diagnosis and as treatment markers, viral load, or the concentration of hepatitis B virus in the blood, is becoming an increasingly important marker for both diagnosis and management of chronic hepatitis
Studies have shown that PEGASYS offers the best chance for a sustained response, in a defined treatment period, for chronic hepatitis
B patients," said Professor Patrick Marcellin, Hepatologist at HE[sup.
We are grateful to Congress for recognizing the need to prioritize chronic hepatitis
B as a serious health issue in the United States," said Molli Conti, the Hepatitis B Foundation's vice president of outreach programs.
The phase III study results in HBeAg-negative chronic hepatitis
B, the most difficult-to-treat form of the disease, were published in September in the New England Journal of Medicine,(ii)and the results of the phase III study in patients with HBeAg-positive chronic hepatitis
B were presented at the 2004 Annual Meeting of the American Association for the Study of Liver Diseases in November.
The Chronic Hepatitis
Cohort Study is nominated for the scientific publication award in the category of data methods and study design, which is one of four categories of the award.
The FDA approval of OLYSIO is an important milestone for people living with chronic hepatitis
C as it means that patients have a new treatment option with the potential to cure this challenging disease.
Now that we have more extensive knowledge of the etiology and pathogenesis of chronic hepatitis
, other hepatitis-related changes that occur in the liver, host factors that can modify the progression of hepatitis, and malignancy-related changes, the role of the liver biopsy has expanded beyond the confirmation of clinical diagnosis, grading the necroinflammatory activity, and staging the extent of fibrosis.
10) This guidance does not apply to people with chronic hepatitis
B who also have hepatitis C, hepatitis D or HIV.
PEGASYS is a pegylated interferon agent that treats chronic hepatitis
C infection with a once-a-week dosage.
Patients with chronic hepatitis
C infection have an increased risk of developing non-Hodgkin's lymphoma and multiple myeloma, based on findings from a study of all notifications of chronic hepatitis
C cases sent to the Swedish Institute for Infectious Disease Control during 1990-2000.
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis
C Virus Infection in HIV-Infected Patients.
To the Editor: Prevalence of chronic hepatitis
C virus (HCV) among blood donors has been assessed in a few West African countries; most recent estimates range from 1.